Fig. 5From: Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancerMatched pair analyses of serum human epidermal growth factor receptor 2 extracellular domain (sHER2) levels at baseline and at surgery (S). *P < 0.05 (exploratory analyses). BL baseline, pCR pathologic complete responseBack to article page